破解企业“基础研究不敢投”困局，上海发布全国首个支持政策

Core Viewpoint - Shanghai has introduced measures to enhance corporate investment in fundamental research, aiming to strengthen the role of enterprises in technological innovation and high-quality development [1][2][4]. Group 1: Policy Measures - The newly released measures include nine specific actions to encourage enterprises to invest in fundamental research, with a maximum annual financial subsidy of 10 million yuan for eligible companies [1][9]. - The "Explorer Program" will be further promoted, which encourages enterprises to engage in fundamental research and collaborate with government bodies [5][6]. - The measures aim to optimize the structure of funding for fundamental research, enhancing the depth and breadth of innovation in technology enterprises [4][8]. Group 2: Current State of Corporate Research Investment - In 2023, enterprises accounted for 77.7% of the total R&D expenditure in China, with a contribution rate of 79.4% to the growth of R&D funding, indicating a solidifying role in innovation [3]. - Despite the growth in R&D funding, there is still a need for increased investment in fundamental research by enterprises, as most focus on experimental development [3][4]. - Shanghai's investment in fundamental research is projected to be around 11% of total R&D expenditure in 2024, surpassing the national average of 6.91% but still below international standards [3][4]. Group 3: Collaborative Efforts and Initiatives - The Explorer Program has expanded from 2 to 22 participating enterprises, covering various fields such as integrated circuits and biomedicine, indicating a growing collaboration between enterprises and research institutions [5][6]. - The establishment of the Shanghai Origin State-owned Assets Innovation Fund aims to support fundamental research through diverse funding channels, addressing the high-risk nature of such investments [15][16]. - Joint research platforms between universities and enterprises have been established, with nearly 20% of university research funding coming from corporate investments, highlighting the importance of collaboration in advancing fundamental research [16][17].